David C Seldin

Summary

Affiliation: Boston University
Country: USA

Publications

  1. ncbi request reprint Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation
    David C Seldin
    Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
    Blood 104:1888-93. 2004
  2. ncbi request reprint CK2 as a positive regulator of Wnt signalling and tumourigenesis
    David C Seldin
    Section of Hematology Oncology, Department of Medicine, Boston University Medical Center, Boston, MA, USA
    Mol Cell Biochem 274:63-7. 2005
  3. pmc RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland
    Elizabeth G Demicco
    Department of Biochemistry, Boston University School of Medicine, 715 Albany Street, Boston, Massachusetts 02118, USA
    Mol Cell Biol 25:10136-47. 2005
  4. ncbi request reprint Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells
    Sean F Eddy
    Department of Biochemistry, Boston University School of Medicine, MA 02118, USA
    Cancer Res 65:11375-83. 2005
  5. ncbi request reprint Protein kinase CK2 is required for dorsal axis formation in Xenopus embryos
    Isabel Dominguez
    Section of Hematology Oncology Department of Medicine, Boston University School of Medicine, Boston MA 02118, USA
    Dev Biol 274:110-24. 2004
  6. doi request reprint Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis
    Saulius Girnius
    Amyloid Treatment and Research Program, Boston University School of Medicine, Boston, MA 02118, USA
    Ann Hematol 89:579-84. 2010
  7. ncbi request reprint High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study
    Martha Skinner
    Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Ann Intern Med 140:85-93. 2004
  8. pmc Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65
    David C Seldin
    Section of Hematology Oncology, Boston University Medical Center, 650 Albany St, Boston, MA 02118, USA
    Blood 108:3945-7. 2006
  9. doi request reprint Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity
    Jian Guan
    Divisions of Cardiovascular Medicine and Genetics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, NRB 431, Boston, MA 02115, USA
    Basic Res Cardiol 108:378. 2013
  10. doi request reprint Amyloid deposits in the bone marrow of patients with immunoglobulin light chain amyloidosis do not impact stem cell mobilization or engraftment
    Andrew J Cowan
    Amyloid Treatment and Research Program, Boston University School of Medicine, Massachusetts, USA
    Biol Blood Marrow Transplant 18:1935-8. 2012

Collaborators

Detail Information

Publications79

  1. ncbi request reprint Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation
    David C Seldin
    Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
    Blood 104:1888-93. 2004
    ..Thus, treatment of AL amyloidosis patients with HDM/SCT produces measurable and sustained improvements in quality of life, particularly in those patients who achieve hematologic CR...
  2. ncbi request reprint CK2 as a positive regulator of Wnt signalling and tumourigenesis
    David C Seldin
    Section of Hematology Oncology, Department of Medicine, Boston University Medical Center, Boston, MA, USA
    Mol Cell Biochem 274:63-7. 2005
    ..Inhibitors of GSK3 under development for treatment of diabetes could promote tumours, while CK2 inhibitors should be useful agents for treatment of cancer...
  3. pmc RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland
    Elizabeth G Demicco
    Department of Biochemistry, Boston University School of Medicine, 715 Albany Street, Boston, Massachusetts 02118, USA
    Mol Cell Biol 25:10136-47. 2005
    ..Inhibition of RelB in breast cancer cells repressed cyclin D1 and c-Myc levels and growth in soft agar. These results implicate RelB/p52 complexes in mammary gland development and carcinogenesis...
  4. ncbi request reprint Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells
    Sean F Eddy
    Department of Biochemistry, Boston University School of Medicine, MA 02118, USA
    Cancer Res 65:11375-83. 2005
    ..Thus, CK2 induces functional IKK-i/IKKepsilon, which is an important mediator of the activation of NF-kappaB that plays a critical role in the pathogenesis of breast cancer...
  5. ncbi request reprint Protein kinase CK2 is required for dorsal axis formation in Xenopus embryos
    Isabel Dominguez
    Section of Hematology Oncology Department of Medicine, Boston University School of Medicine, Boston MA 02118, USA
    Dev Biol 274:110-24. 2004
    ..Taken together, these studies demonstrate that CK2 is a bona fide member of the Wnt pathway and has a critical role in the establishment of the dorsal embryonic axis...
  6. doi request reprint Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis
    Saulius Girnius
    Amyloid Treatment and Research Program, Boston University School of Medicine, Boston, MA 02118, USA
    Ann Hematol 89:579-84. 2010
    ..Hematologic relapses occurred in 60% of patients at a median of 1 year after HDM/SCT. In conclusion, HDM/SCT can prolong overall survival in patients with MM/AL who are eligible to receive it...
  7. ncbi request reprint High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study
    Martha Skinner
    Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Ann Intern Med 140:85-93. 2004
    ..AL amyloidosis is a fatal disease resulting from tissue deposition of amyloid fibrils derived from monoclonal immunoglobulin light chains. Treatment with oral chemotherapy is minimally effective...
  8. pmc Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65
    David C Seldin
    Section of Hematology Oncology, Boston University Medical Center, 650 Albany St, Boston, MA 02118, USA
    Blood 108:3945-7. 2006
    ....
  9. doi request reprint Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity
    Jian Guan
    Divisions of Cardiovascular Medicine and Genetics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, NRB 431, Boston, MA 02115, USA
    Basic Res Cardiol 108:378. 2013
    ..Collectively, this work identifies STC1 as a critical determinant of AL-LC cardiotoxicity. ..
  10. doi request reprint Amyloid deposits in the bone marrow of patients with immunoglobulin light chain amyloidosis do not impact stem cell mobilization or engraftment
    Andrew J Cowan
    Amyloid Treatment and Research Program, Boston University School of Medicine, Massachusetts, USA
    Biol Blood Marrow Transplant 18:1935-8. 2012
    ..Thus, our data indicate that although amyloid involvement of the bone marrow is common, it does not negatively affect stem cell mobilization or neutrophil and platelet engraftment after HDM-SCT...
  11. pmc Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: a case report with literature review
    Martin Tam
    Graduate Medical Sciences Division, Boston University School of Medicine, Boston, Massachusetts, USA
    Amyloid 16:103-7. 2009
    ..A literature review of spontaneous liver rupture in patients with amyloidosis is presented...
  12. pmc The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development
    David Y Lou
    Boston University Medical Center, 650 Albany Street, Boston, MA 02118, USA
    Mol Cell Biol 28:131-9. 2008
    ..Defects in the formation of the heart lead to hydrops fetalis and are likely the cause of embryonic lethality. Thus, CK2alpha appears to play an essential and uncompensated role in mammalian development...
  13. pmc Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish
    Shikha Mishra
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am J Physiol Heart Circ Physiol 305:H95-103. 2013
    ..Furthermore, this in vivo model system will allow for further study of the molecular underpinnings of AL cardiotoxicity and identification of novel therapeutic strategies. ..
  14. ncbi request reprint Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis
    Marganit Farago
    Molecular Medicine Program, Department of Medicine, Boston University Medical Center, Boston, Massachusetts, USA
    Cancer Res 65:5792-801. 2005
    ..Thus, antagonism of GSK3beta activity is oncogenic in the mammary epithelium; mutation or pharmacologic down-regulation of GSK3beta could promote mammary tumors...
  15. pmc Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment
    David C Seldin
    Amyloidosis Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston Medical Center, K5, 72 East Concord Street, Boston, MA 02118, USA
    Heart Fail Clin 7:385-93. 2011
    ..Growing numbers of treatment options exist for these diseases, and timely diagnosis and institution of therapy is essential for preservation of cardiac function...
  16. pmc Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis
    Komei Tanaka
    Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA
    J Am Heart Assoc 2:e005868. 2013
    ..We therefore tested the hypothesis that circulating levels of MMPs and TIMPs in patients with AL-CMP and TTR-related CMP (TTR-CMP) are dissimilar and indicative of cardiac amyloid disease type...
  17. doi request reprint A new lysozyme tyr54asn mutation causing amyloidosis in a family of Swedish ancestry with gastrointestinal symptoms
    Saulius Girnius
    Amyloid Treatment and Research Program, Boston University School of Medicine, MA, USA
    Amyloid 19:182-5. 2012
    ..There was no associated nephropathy as has been reported for other ALys mutations. We describe a new mutant lysozyme that presents with abdominal discomfort, diarrhea, weight loss, and sicca syndrome...
  18. doi request reprint Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis
    Vaishali Sanchorawala
    Section of Hematology Oncology, Department of Medicine, Boston University School of Medicine, 820 Harrison Avenue, Boston, MA 02118, USA
    Clin Lymphoma Myeloma Leuk 10:469-72. 2010
    ..However, only selected patients with AL amyloidosis are eligible for HDM/SCT because of amyloid-associated organ dysfunction...
  19. ncbi request reprint Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype
    Karine Belguise
    Departments of Biochemistry, Boston University School of Public Health, Boston, Massachusetts, USA
    Cancer Res 67:11742-50. 2007
    ..Thus, activation of c-Rel and CK2 and downstream targets AhR and Slug by DMBA induces EMT; EGCG can inhibit this signaling...
  20. ncbi request reprint Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis
    Amit Fadia
    The Renal Section, Stem Cell Transplant Program of the Hematology Oncology Section, and Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
    Kidney Int 63:1868-73. 2003
    ..The incidence and outcome of ARF as a complication of such treatment is not known...
  21. doi request reprint Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis
    Lawreen H Connors
    Amyloid Treatment and Research Program, Boston University School of Medicine, Boston, MA 02118, USA
    Am Heart J 158:607-14. 2009
    ..9%. This retrospective study describes TTR V122I-associated cardiac amyloid disease (ATTR) in a major amyloid referral clinic population...
  22. ncbi request reprint Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors
    Nicolas Currier
    Boston University School of Medicine, Department of Medicine, Boston, MA, USA
    Toxicol Pathol 33:726-37. 2005
    ..These data suggest that environmental carcinogens can produce long-lasting alterations in growth and anti-apoptotic pathways, leading to mammary tumorigenesis...
  23. doi request reprint Immunoglobulin light chain, Blimp-1 and cytochrome P4501B1 peptides as potential vaccines for AL amyloidosis
    Amanda Flies
    Department of Pathology, University of Massachusetts Medical School, Worcester, MA, USA
    Immunol Cell Biol 90:528-39. 2012
    ..These studies suggest that AL amyloidosis, with its relatively low tumor cell burden, may be an attractive target for peptide-based multivalent vaccines...
  24. pmc CK2α is essential for embryonic morphogenesis
    Isabel Dominguez
    Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    Mol Cell Biochem 356:209-16. 2011
    ..Here, we summarize the overall phenotype found in CK2α (-/- ) mice and describe our initial analysis aimed to identify the cellular processes affected in CK2α mutants...
  25. pmc Developmental and growth defects in mice with combined deficiency of CK2 catalytic genes
    Esther Landesman-Bollag
    Section of Hematology Oncology, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA 02118, USA
    Mol Cell Biochem 356:227-31. 2011
    ..Fibroblasts derived from CK2α+/-CK2α'-/- embryos grew poorly in culture. These experiments demonstrate that combined loss of one CK2α allele and both CK2α' alleles leads to unique abnormalities of growth and development...
  26. pmc Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition
    Andreia Biolo
    Whitaker Cardiovascular Institute, Boston University School of Medicine, 715 Albany Street, Boston, MA 02118, USA
    Circ Heart Fail 1:249-57. 2008
    ....
  27. pmc Threonine 393 of beta-catenin regulates interaction with Axin
    Hao Wu
    Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Cell Biochem 108:52-63. 2009
    ..In addition, the increased recruitment of GSK3beta to the destruction complex in the presence of activated beta-catenin mutants could be a feedback mechanism to suppress overactive Wnt signaling...
  28. ncbi request reprint Association of acquired von Willebrand syndrome with AL amyloidosis
    Cynthia A Kos
    Department of Medicine, Boston University Medical Center, Boston, Massachusetts, USA
    Am J Hematol 82:363-7. 2007
    ..AVWS should be considered in AL amyloidosis patients with hemorrhagic diatheses and normal clotting factor levels...
  29. pmc Gene targeting of CK2 catalytic subunits
    David C Seldin
    Department of Medicine, Boston University School of Medicine and Boston Medical Center, 650 Albany Street, Boston, MA 02118, USA
    Mol Cell Biochem 316:141-7. 2008
    ....
  30. ncbi request reprint Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
    Vaishali Sanchorawala
    Department of Medicine, F 302, 732 Harrison Ave, Boston University Medical Center, MA 02118, USA
    Blood 109:492-6. 2007
    ..Findings from this trial indicate that lenalidomide can be effective in treating AL amyloidosis...
  31. doi request reprint Myocardial infarction with "clean coronaries" caused by amyloid light-chain AL amyloidosis: a case report and literature review
    Stephanie B Tsai
    Amyloid Treatment and Research Program, Boston Medical Center, 820 Harrison Avenue, Boston, MA, USA
    Amyloid 18:160-4. 2011
    ..Contemporary testing should aim to detect both forms of cardiac amyloidosis, which may impact management and prognosis...
  32. ncbi request reprint A role for CK2alpha/beta in Xenopus early embryonic development
    Isabel Dominguez
    Hematology Oncology Section, Department of Medicine, Boston University Medical School, Boston, MA, USA
    Mol Cell Biochem 274:125-31. 2005
    ..Our results demonstrate that CK2 is required for dorsal axis formation and is for normal upregulation of Wnt signaling genes and targets. Thus, CK2 is a regulator of endogenous axis formation in vertebrates...
  33. ncbi request reprint High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease
    Liam F Casserly
    Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Kidney Int 63:1051-7. 2003
    ..The efficacy and tolerability of such treatment for patients with AL amyloidosis-associated ESRD are unknown...
  34. pmc Kidney dysfunction during lenalidomide treatment for AL amyloidosis
    Richard Specter
    Renal Section, Boston University School of Medicine, Boston, MA, USA
    Nephrol Dial Transplant 26:881-6. 2011
    ..The objective of this study is to characterize alterations in kidney function among patients with AL amyloidosis undergoing treatment with lenalidomide...
  35. pmc Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease
    Saulius Girnius
    Department of Medicine, Boston University School of Medicine, Boston University School of Public Health, Boston, MA, USA
    Haematologica 94:1029-32. 2009
    ..In conclusion, hepatic disease improves in almost 2/3 patients treated with high-dose intravenous melphalan and autologous stem cell transplantation who have a complete or partial hematologic response to treatment...
  36. pmc Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial
    Vaishali Sanchorawala
    Amyloid Treatment and Research Program, Section of Hematology and Oncology, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA
    Haematologica 98:789-92. 2013
    ..In conclusion, this combination is associated with significant myelosuppression leading to dose modifications and producing minor hematologic responses in AL amyloidosis. http://clinicaltrials.gov/ct2/show/NCT00679367...
  37. pmc Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors
    Raphaelle Romieu-Mourez
    Department of Biochemistry, Boston University Medical School, Boston, Massachusetts 02118, USA
    Mol Cell Biol 23:5738-54. 2003
    ..These results indicate for the first time that dysregulated expression of c-Rel, as observed in breast cancers, is capable of contributing to mammary tumorigenesis...
  38. pmc Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis
    Jennifer Ellis Ward
    Amyloid Treatment and Research Program, and Department of Medicine, Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA 02118, USA
    Blood 118:6610-7. 2011
    ..The CMV-λ6 transgenic model replicates the process of AL amyloidosis and is useful for testing the antifibril potential of orally available agents...
  39. pmc Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
    Maria Teresa Cibeira
    Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    Blood 118:4346-52. 2011
    ..9 years, respectively. Thus, treatment of selected AL patients with HDM/SCT resulted in a high organ response rate and long OS, even for those patients who did not achieve CR...
  40. pmc Dynamic expression of a LEF-EGFP Wnt reporter in mouse development and cancer
    Nicolas Currier
    Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
    Genesis 48:183-94. 2010
    ..Thus, this transgenic line is useful for ex vivo and in vitro studies of Wnt signaling in development and cancer...
  41. ncbi request reprint A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis
    Jennifer J Schlezinger
    Department of Environmental Health, Boston University School of Public Health, Boston, MA 02118, USA
    Biol Chem 387:1175-87. 2006
    ..The theme that malignant cells reveal the functions for which the AhR has been evolutionarily conserved is presented throughout this discussion...
  42. doi request reprint Overexpression of human amyloidogenic light chains causes heart failure in embryonic zebrafish: a preliminary report
    Jordan T Shin
    Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Amyloid 19:191-6. 2012
    ..This model will allow exploration of amyloid pathophysiology and testing of interventions to reduce and reverse the deleterious effects of amyloidosis on myocardial function...
  43. pmc Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by Blimp-1-dependent repression of BMP-5
    Mathilde Romagnoli
    Department of Biochemistry, Tufts University School of Medicine, Boston, MA 02111, USA
    Cancer Res 72:6268-78. 2012
    ..Thus, the Ras effector Blimp-1 plays an essential role in TGF-β1-induced EMT via repression of BMP-5 in breast cancer...
  44. doi request reprint Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: a case report and literature review
    Benjamin Freeman
    Section of Hematology and Oncology, Boston University School of Medicine, Boston, MA, USA
    Amyloid 19:156-60. 2012
    ..A literature review of thrombembolic complications in patients with amyloidosis is presented...
  45. ncbi request reprint CK2 phosphorylation of the armadillo repeat region of beta-catenin potentiates Wnt signaling
    Diane H Song
    Department of Medicine, Boston University Medical Center, Boston University, Boston, Massachusetts 02118, USA
    J Biol Chem 278:24018-25. 2003
    ..Thus, CK2 is a positive regulator of Wnt signaling through phosphorylation of beta-catenin at Thr393, leading to proteasome resistance and increased protein and co-transcriptional activity...
  46. doi request reprint Macroglossia - not always AL amyloidosis
    Andrew J Cowan
    Department of Medicine, Amyloid Treatment and Research Program, Boston University School of Medicine, Boston Medical Center, Massachusetts, USA
    Amyloid 18:83-6. 2011
    ....
  47. ncbi request reprint Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis
    Vaishali Sanchorawala
    Department of Medicine, Section of Hematology Oncology, Boston Medical Center, Boston University School of Medicine, 88 East Newton Street, Boston, MA 02118, USA
    Br J Haematol 117:886-9. 2002
    ..This regimen appeared to be effective in inducing haematological responses in patients who received total doses of melphalan > 300 mg...
  48. pmc Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation
    Vaishali Sanchorawala
    Stem Cell Transplantation Program of the Section of Hematology Oncology, Boston University School of Medicine, Boston, MA 02118, USA
    Blood 110:3561-3. 2007
    ..001). In conclusion, HDM/SCT leads to durable remissions and prolonged survival, particularly for those patients who achieve a hematologic CR...
  49. pmc Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience
    Andrew J Cowan
    Amyloid Treatment and Research Program, Boston University School of Medicine, Boston, MA, USA
    Haematologica 98:141-6. 2013
    ..Although a rare manifestation of amyloidosis, staining for amyloid should be considered in patients undergoing gastrointestinal biopsy who have unexplained chronic gastrointestinal symptoms...
  50. pmc Evidence for a functional role of the molecular chaperone clusterin in amyloidotic cardiomyopathy
    Michael J Greene
    Department of Pathology, Boston University School of Medicine, Boston, Massachusetts, USA
    Am J Pathol 178:61-8. 2011
    ..Taken together, these results suggest that CLU may play a pathogenetic role in TTR and Ig light chain amyloidoses and amyloidotic CMP...
  51. ncbi request reprint Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis
    Harun Akar
    Amyloid Treatment and Research Program at Boston Medical Center, Boston University School of Medicine, Boston, MA, 02118, USA
    Amyloid 12:210-5. 2005
    ..After a histologic tissue diagnosis of amyloidosis, determining the type as AL amyloidosis relies on a panel of hematologic tests to determine light chain clonality and the exclusion other forms of amyloidosis...
  52. ncbi request reprint Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis
    David C Seldin
    Boston University Medical Center, Boston Medical Center, MA, USA
    Clin Lymphoma 3:241-6. 2003
    ..No complete hematologic responses were seen, but 25% of patients had a significant reduction in Bence-Jones proteinuria. Thus, while thalidomide has activity in AL amyloidosis, it also has significant toxicity in this patient population...
  53. ncbi request reprint Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis
    John L Berk
    Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
    Chest 124:969-77. 2003
    ..We hypothesized that disruption of pleural function by amyloid deposits underlies persistent pleural effusions (PPEs) in patients with AL disease...
  54. pmc Loss of AND-34/BCAR3 expression in mice results in rupture of the adult lens
    Richard I Near
    Department of Medicine, Boston Medical Center, Boston, MA 2118, USA
    Mol Vis 15:685-99. 2009
    ..Expression of AND-34 regulates epithelial cell growth pattern, motility, and growth factor dependence. We sought to establish the effects of the loss of AND-34 expression in a mammalian organism...
  55. doi request reprint Dysregulation of miRNAs in AL amyloidosis
    Liangping Weng
    Amyloid Treatment and Research Program, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA
    Amyloid 18:128-35. 2011
    ..Our data suggests that miRNAs are dysregulated in clonal plasma cells in AL amyloidosis and may be potentially useful as biomarkers of disease...
  56. pmc Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue
    Francesca Lavatelli
    Amyloid Treatment and Research Program, Boston, Massachusetts, USA
    Mol Cell Proteomics 7:1570-83. 2008
    ....
  57. pmc Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway
    Jianru Shi
    Cardiac Muscle Research Laboratory, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 107:4188-93. 2010
    ....
  58. ncbi request reprint Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells
    Raphaelle Romieu-Mourez
    Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118 2394, USA
    Cancer Res 62:6770-8. 2002
    ....
  59. ncbi request reprint Direct identification of PTEN phosphorylation sites
    Susan J Miller
    Cancer Biology Program, Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    FEBS Lett 528:145-53. 2002
    ....
  60. doi request reprint Localized amyloidosis of the breast: a case series
    Marjory Charlot
    Section of Hematology and Oncology, Department of Medicine, Boston Medical Center, MA, USA
    Amyloid 18:72-5. 2011
    ..Thus, other than excisional biopsy to exclude malignancy, no systemic therapy is indicated for this disorder...
  61. pmc Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL
    Vipul C Chitalia
    Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Nat Cell Biol 10:1208-16. 2008
    ..The pVHL tumour suppressor and the Wnt tumorigenesis pathway are therefore directly linked through Jade-1...
  62. doi request reprint The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain
    Elena S Klimtchuk
    Gerry Amyloid Research Laboratory, Amyloid Treatment and Research Center, Department of Medicine, Boston University School of Medicine, 72 East Concord Street, Boston, Massachusetts 02118, United States
    Biochemistry 49:9848-57. 2010
    ..The kinetic barrier for this aggregation is regulated by the stability of the V(L) region. This represents a paradigm shift in AL fibrillogenesis and suggests C(L) region as a potential therapeutic target...
  63. ncbi request reprint Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival
    Tatiana Prokaeva
    Boston University School of Medicine, Boston, Massachusetts 02118 2526, USA
    Arthritis Rheum 56:3858-68. 2007
    ....
  64. pmc Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils
    Ruiyi Ren
    Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Biol Chem 285:37672-82. 2010
    ..These findings highlight the importance of the variable and constant LC regions in GAG interaction and suggest potential therapeutic targets for treatment...
  65. pmc Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure
    Bimalangshu R Dey
    Massachusetts General Hospital, Boston, MA, USA
    Transplantation 90:905-11. 2010
    ..Autologous stem-cell transplantation (ASCT) has become a common therapy for AL amyloidosis, but there is an exceedingly high treatment-related mortality in patients with heart failure...
  66. doi request reprint AL-Base: a visual platform analysis tool for the study of amyloidogenic immunoglobulin light chain sequences
    Kip Bodi
    Amyloid Treatment and Research Program, Alan and Sandra Gerry Amyloid Research Laboratory, Boston University School of Medicine, 715 Albany Street, Boston, MA 02118, USA
    Amyloid 16:1-8. 2009
    ..The likelihood that each sequence has evolved through somatic hypermutation can be predicted using an automated binomial or multinomial distribution model. AL-Base is available to the scientific community for research purposes...
  67. doi request reprint Amyloidomics comes of age
    David C Seldin
    Boston University School of Medicine, USA
    Blood 119:1795-6. 2012
    ..In this issue of Blood, Brambilla et al report a new methodology for accomplishing the key third step in this process...
  68. pmc Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kappa1 immunoglobulin light chains
    Lawreen H Connors
    Alan and Sandra Gerry Amyloid Research Laboratory in the Amyloid Treatment and Research Program, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Biochemistry 46:14259-71. 2007
    ..This study demonstrated the extensive heterogeneity in primary structure, post-translational modifications, and germline gene usage that occurred in nine amyloidogenic kappa1 LC proteins...
  69. ncbi request reprint An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis
    Vaishali Sanchorawala
    Section of Hematology Oncology in the Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
    Amyloid 14:261-9. 2007
    ..This review outlines an overview of high-dose intravenous melphalan and stem cell transplantation in the treatment of AL amyloidosis. An algorithm of our recommendations for the treatment of AL amyloidosis is also outlined...
  70. pmc Impaired 3',5'-cyclic adenosine monophosphate-mediated signaling in immediate early responsive gene X-1-deficient vascular smooth muscle cells
    Mohd Shahid
    Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Wellman Center for Photomedicine, Boston, Mass 02114, USA
    Hypertension 56:705-12. 2010
    ....
  71. ncbi request reprint Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis
    Padmalatha Channavajhala
    Department of Microbiology, Boston University School of Medicine, Boston, Massachusetts, MA 02118, USA
    Oncogene 21:5280-8. 2002
    ..Thus, CK2 is a critical regulator of c-myc protein stability and of the proliferation of these T cell lymphomas...
  72. ncbi request reprint Diagnosis and treatment of Al amyloidosis
    David C Seldin
    Amyloidosis Treatment and Research Center, Boston University School of Medicine, MA, USA
    Clin Adv Hematol Oncol 1:154-5. 2003
  73. pmc The A2B adenosine receptor protects against inflammation and excessive vascular adhesion
    Dan Yang
    Department of Biochemistry and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Clin Invest 116:1913-23. 2006
    ..Hence, we identify the A2BAR as a new critical regulator of inflammation and vascular adhesion primarily via signals from hematopoietic cells to the vasculature, focusing attention on the receptor as a therapeutic target...
  74. ncbi request reprint T1alpha, a lung type I cell differentiation gene, is required for normal lung cell proliferation and alveolus formation at birth
    Maria I Ramirez
    Pulmonary Center, Boston University School of Medicine, Boston, MA 02118, USA
    Dev Biol 256:61-72. 2003
    ....
  75. ncbi request reprint Xth International Symposium on Amyloid and Amyloidosis April 18-22, 2004 (selected highlights) Tours, Loire Valley, France
    Jean D Sipe
    Emerita, Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA
    Amyloid 11:268-72. 2004
  76. ncbi request reprint AL amyloidosis, a curable disease?
    David C Seldin
    Amyloid 9:203-6. 2002
  77. ncbi request reprint Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors
    Keiko Miyoshi
    Laboratory of Genetics and Physiology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, MD 20892, USA
    Oncogene 21:5548-56. 2002
    ....
  78. pmc Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors
    Andrea Rosner
    Center for Comparative Medicine, University of California, Davis 95616, USA
    Am J Pathol 161:1087-97. 2002
    ....
  79. ncbi request reprint Adapting to AL amyloidosis
    David C Seldin
    Haematologica 91:1591-5. 2006